Taysha Gene Therapies Total Non-Operating Income/Expense 2020-2024 | TSHA

Taysha Gene Therapies total non-operating income/expense from 2020 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.
Taysha Gene Therapies Annual Total Non-Operating Income/Expense
(Millions of US $)
2023 $-39
2022 $-4
2021 $-1
2020 $-17
2019 $
Taysha Gene Therapies Quarterly Total Non-Operating Income/Expense
(Millions of US $)
2024-06-30 $0
2024-03-31 $0
2023-12-31 $64
2023-09-30 $-101
2023-06-30 $-1
2023-03-31 $-1
2022-12-31 $-1
2022-09-30 $-1
2022-06-30 $-1
2022-03-31 $-1
2021-12-31 $-1
2021-09-30 $-1
2021-06-30 $-0
2021-03-31 $0
2020-12-31 $0
2020-09-30 $-0
2020-06-30 $-17
2020-03-31 $0
2019-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.307B $0.015B
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.384B 6.36
Dr Reddy's Laboratories (RDY) India $12.612B 24.14
BridgeBio Pharma (BBIO) United States $5.094B 0.00
Bausch Health Cos (BHC) Canada $3.435B 2.49
Amphastar Pharmaceuticals (AMPH) United States $2.352B 13.96
Supernus Pharmaceuticals (SUPN) United States $2.021B 27.52
Personalis (PSNL) United States $0.241B 0.00
Assembly Biosciences (ASMB) United States $0.106B 0.00
Sol-Gel Technologies (SLGL) Israel $0.016B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00